Pharmaceutical firms are urged to capitalise on current trends in AD trials. The atopic dermatitis (AD) market is projected ...

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click ...

The U.S. Food and Drug Administration has approved Eli Lilly's Ebglyss (lebrikizumab-lbkz) for adults and children aged 12 ...

Atopic dermatitis, a chronic skin condition, is common in children and requires treatment to minimise frequent flares. Dr Ker ...

Introduction: Eczema, also known as atopic dermatitis, is a common skin condition characterized by dry, itchy skin. While ...

The atopic dermatitis (AD) market is projected to reach $16.7 billion by 2030, according to GlobalData. New therapies like ...

中国网9月14日讯（记者王一辰）9 月 14 日是第七个的“世界特应性皮炎日” (World Atopic Dermatitis ...

异位性皮肤炎不仅会伤害患者的皮肤，也可能影响生活质量和日常活动。新加坡中央医院将在9月13日（星期五）举办“异位性皮肤炎——不止是皮肤表层问题”（Atopic Dermatitis – More than skin deep?）线上英语讲座。

Dupilumab decreases general and type 2 inflammatory biomarker levels in children with moderate to severe atopic dermatitis.

Ebglyss is a new biologic treatment for moderate-to-severe eczema that isn’t controlled with topical therapies. The ...

在社交媒体光鲜滤镜的背后，许多饱受特应性皮炎困扰的患者往往会通过“精修”的图片来“隐藏”皮肤问题，而他们在日常生活中遭受的挑战也常被公众忽视和误解。作为皮肤科的“一号疾病”，特应性皮炎（Atopic Dermatitis，简称“AD”）具有遗传性和家族史的特征，属于免疫介导炎症性疾病（简称IMID），我国现有高达3000万人深受其扰，主要表现为湿疹样皮疹和难以忍受的剧烈瘙痒。